Linked Life Data

19595877

Source:http://linkedlifedata.com/resource/pubmed/id/19595877

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-7-14
pubmed:abstractText
Balancing benefits and risks in the development of treatments for Alzheimer's disease is challenging given the nature of the disease but critically important to ensure effective treatments are available. Drawing on a diverse panel of scientists, regulators, caregivers, patients and advocates convened by the Alzheimer's Association, insights are offered into benefit/risk assessment, decision-making, regulatory and societal factors affecting clinical trials on AD. Several policy solutions are offered to improve the drug testing, review and approval process.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:month
Jul
pubmed:issn
1552-5279
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
160-3
pubmed:year
2006
pubmed:articleTitle
Perspectives on assessing benefits and risks in clinical trials for Alzheimer's disease.
pubmed:affiliation
Alzheimer's Association, Washington, DC, USA. Stephen.McConnell@alz.org
pubmed:publicationType
Journal Article